Bli medlem
Bli medlem

Du är här


Karolinska Development AB (publ): Karolinska Development's portfolio company Forendo Pharma announces the appointment of Da...

STOCKHOLM, March 7, 2018. Karolinska Development's portfolio company Forendo
Pharma today announces the appointment of David Colpman as a non-executive
Board Director. David brings with him an impressive career of more than 25
years in pharma and biotech business development and strategy. His previous
roles include Head of Global Business Development at the Irish biotechnology
company Shire and business development and commercial positions at Glaxo
Wellcome and Novo Nordisk. David has a degree in Pharmacy and he also serves
on the Boards of Orexo AB and HRA Pharma Ltd.

Forendo Pharma is developing tissue-specific hormone inhibitors to rebalance
local estrogen metabolism in the gynaecological condition endometriosis
lesions. The key differentiator of the company's drug candidate FOR-6219,
compared to other drug treatments in the market or in clinical development is
the ability to act locally without impacting the systemic estrogen levels, as
demonstrated in preclinical models.

"I am very excited to join the Forendo Board. The company is developing a
truly novel therapy, for the large unmet needs of this disease, that affects
as many as 10% of all women in reproductive age" David Colpman says. "I see
great opportunities for Forendo, and look forward to working with the
experienced team in the company"

"We are delighted to welcome David with his broad experience in the industry
that will be of significant benefit to Forendo", said Risto Lammintausta, CEO
of Forendo Pharma, "His insights and expertise will be very helpful as we
continue to evaluate the commercial alternatives of our programs."

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:


About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough medical
innovations in the Nordic region that are developed by entrepreneurs and
leadership teams. The Company invests in the creation and growth of companies
that advance these assets into commercial products that are designed to make
a difference to patients' lives while providing an attractive return on
investment to shareholders.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes
in the Nordic region. The Company aims to build companies around scientists
who are leaders in their fields, supported by experienced management teams
and advisers, and co-funded by specialist international investors, to provide
the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with
a proven track record as company builders and with access to a strong global

For more information, please

KD News release Forendo March 18

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.